JP2017533248A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533248A5 JP2017533248A5 JP2017525075A JP2017525075A JP2017533248A5 JP 2017533248 A5 JP2017533248 A5 JP 2017533248A5 JP 2017525075 A JP2017525075 A JP 2017525075A JP 2017525075 A JP2017525075 A JP 2017525075A JP 2017533248 A5 JP2017533248 A5 JP 2017533248A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolo
- pyridin
- oxo
- enyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077703P | 2014-11-10 | 2014-11-10 | |
| US62/077,703 | 2014-11-10 | ||
| PCT/US2015/060003 WO2016077378A1 (en) | 2014-11-10 | 2015-11-10 | Substituted pyrrolopyrdines as inhibitors of bromodomain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533248A JP2017533248A (ja) | 2017-11-09 |
| JP2017533248A5 true JP2017533248A5 (enExample) | 2018-12-20 |
| JP6669744B2 JP6669744B2 (ja) | 2020-03-18 |
Family
ID=54608969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525075A Expired - Fee Related JP6669744B2 (ja) | 2014-11-10 | 2015-11-10 | ブロモドメインのインヒビターとしての置換ピロロピリジン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10183009B2 (enExample) |
| EP (1) | EP3218375B1 (enExample) |
| JP (1) | JP6669744B2 (enExample) |
| CN (3) | CN107207493B (enExample) |
| MA (1) | MA40943A (enExample) |
| WO (1) | WO2016077378A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA035469B1 (ru) | 2013-03-15 | 2020-06-22 | Инсайт Холдингс Корпорейшн | Трициклические гетероциклы как ингибиторы белков бэт |
| AU2014257051A1 (en) | 2013-04-24 | 2015-11-19 | Salk Institute For Biological Studies | Vitamin D receptor/SMAD genomic circuit gates fibrotic response |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| SMT202000133T1 (it) | 2014-04-23 | 2020-05-08 | Incyte Corp | 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet |
| JP6599979B2 (ja) | 2014-09-15 | 2019-10-30 | インサイト・コーポレイション | Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物 |
| JP6639497B2 (ja) * | 2014-11-10 | 2020-02-05 | ジェネンテック， インコーポレイテッド | ブロモドメインインヒビターおよびその使用 |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| WO2016123391A1 (en) | 2015-01-29 | 2016-08-04 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| EP3265453B1 (en) * | 2015-03-05 | 2022-06-29 | Boehringer Ingelheim International GmbH | New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9 |
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| WO2017075377A1 (en) | 2015-10-29 | 2017-05-04 | Incyte Corporation | Amorphous solid form of a bet protein inhibitor |
| CN109715625B (zh) | 2016-06-20 | 2022-04-19 | 因赛特公司 | Bet抑制剂的结晶固体形式 |
| WO2018130174A1 (zh) * | 2017-01-11 | 2018-07-19 | 江苏豪森药业集团有限公司 | 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用 |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| WO2018137655A1 (zh) * | 2017-01-25 | 2018-08-02 | 江苏豪森药业集团有限公司 | 吡咯并吡啶类n-氧化衍生物及其制备方法和应用 |
| US20210130346A1 (en) * | 2017-04-14 | 2021-05-06 | Abbvie Inc. | Bromodomain Inhibitors |
| WO2019023149A1 (en) | 2017-07-24 | 2019-01-31 | Salk Institute For Biological Studies | USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES |
| TWI713952B (zh) | 2017-12-20 | 2020-12-21 | 大陸商貝達藥業股份有限公司 | 作為溴結構域蛋白質抑制劑的化合物和組合物 |
| CN109970733B (zh) * | 2017-12-28 | 2020-05-08 | 新发药业有限公司 | 一种维罗非尼及其类似物的简便制备方法 |
| US10442799B1 (en) | 2018-04-07 | 2019-10-15 | Fuqiang Ruan | Heterocyclic compounds and uses thereof |
| CN110577526B (zh) * | 2018-06-07 | 2023-10-27 | 上海翰森生物医药科技有限公司 | 溴域结构蛋白抑制剂的盐及其制备方法和应用 |
| CN110372693B (zh) * | 2018-07-04 | 2022-05-03 | 清华大学 | 一种靶向降解bet蛋白的化合物及其应用 |
| CN110776508B (zh) * | 2018-07-27 | 2021-07-16 | 海创药业股份有限公司 | 一种brd4抑制剂及其制备方法和用途 |
| CN110818609A (zh) * | 2018-08-11 | 2020-02-21 | 中国药科大学 | 3-乙酰基吲哚类brpf1抑制剂的制备方法及其用途 |
| US12636290B2 (en) * | 2018-12-20 | 2026-05-26 | Saint Louis University | BET inhibitors for modulating DUX4 expression in FSHD |
| WO2020160193A2 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| WO2020160192A1 (en) | 2019-01-29 | 2020-08-06 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| WO2021022163A2 (en) | 2019-07-31 | 2021-02-04 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| MX2022009308A (es) | 2020-01-29 | 2022-08-22 | Foghorn Therapeutics Inc | Compuestos y usos de estos. |
| US12528825B2 (en) | 2020-01-29 | 2026-01-20 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| CN119823124A (zh) | 2020-03-05 | 2025-04-15 | C4医药公司 | 用于brd9的靶向降解的化合物 |
| WO2021233371A1 (zh) * | 2020-05-21 | 2021-11-25 | 贝达药业股份有限公司 | 作为溴结构域蛋白质抑制剂的化合物和组合物 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| US11787800B2 (en) | 2020-07-29 | 2023-10-17 | Foghorn Therapeutics Inc. | BRD9 degraders and uses thereof |
| WO2022025880A1 (en) * | 2020-07-29 | 2022-02-03 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| US12617787B2 (en) * | 2020-11-30 | 2026-05-05 | Lee Moffitt Cancer Center and Research Institute, Inc. | Merged scaffold TAF1 inhibitors |
| CN115232123B (zh) * | 2021-04-23 | 2026-06-12 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| US11767330B2 (en) | 2021-07-06 | 2023-09-26 | Foghorn Therapeutics Inc. | Citrate salt, pharmaceutical compositions, and methods of making and using the same |
| JP2025525347A (ja) | 2022-06-16 | 2025-08-05 | アンフィスタ セラピューティクス リミテッド | 標的タンパク質分解のための新規の二官能性分子 |
| AU2023343029A1 (en) | 2022-09-13 | 2025-03-27 | Amphista Therapeutics Limited | Compounds for targeted protein degradation |
| WO2024193527A1 (zh) * | 2023-03-20 | 2024-09-26 | 山东新时代药业有限公司 | 作为溴结构域抑制剂的吡咯并[2,3-c]吡啶类化合物 |
| WO2025117674A1 (en) * | 2023-11-28 | 2025-06-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compounds for targeted degradation of taf1 |
| GB202319256D0 (en) | 2023-12-15 | 2024-01-31 | Amphista Therapeutics Ltd | Novel compounds for targeted protein degradation |
| WO2025191109A1 (en) | 2024-03-13 | 2025-09-18 | Amphista Therapeutics Limited | Combinations comprising brd9 bifunctional compounds and their use in the treatment of cancer |
| WO2026052822A1 (en) | 2024-09-06 | 2026-03-12 | Amphista Therapeutics Limited | Tetrahydroisoquinoline compounds for targeted protein degradation |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| DE69025946T2 (de) | 1989-09-08 | 1996-10-17 | Univ Duke | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| KR100441557B1 (ko) | 1994-07-21 | 2005-08-05 | 아크조 노벨 엔.브이. | 고리형케톤과산화물조성물 |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| US6391874B1 (en) | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| AU1308799A (en) | 1997-11-06 | 1999-05-31 | American Cyanamid Company | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| CN1160338C (zh) | 1998-11-19 | 2004-08-04 | 沃尼尔·朗伯公司 | N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂 |
| JP2007291059A (ja) * | 2005-11-21 | 2007-11-08 | Japan Tobacco Inc | ヘテロ環化合物およびその医薬用途 |
| AR057986A1 (es) * | 2005-11-21 | 2008-01-09 | Japan Tobacco Inc | Compuesto heterociclico y su uso farmaceutico |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US20140094456A1 (en) * | 2012-10-02 | 2014-04-03 | Intermune, Inc. | Anti-fibrotic pyridinones |
| AR092742A1 (es) * | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| WO2014125408A2 (en) * | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors |
| EP2970285B1 (en) | 2013-03-11 | 2019-04-17 | AbbVie Inc. | Fused tetracyclic bromodomain inhibitors |
| BR112015022391B1 (pt) * | 2013-03-12 | 2021-12-21 | Abbvie Inc | Compostos inibidores do domínio bromo tetracíclico, composição farmacêutica que compreende os referidos compostos e usos terapêuticos dos mesmos |
| CN104211639A (zh) | 2013-06-05 | 2014-12-17 | 中国科学院上海药物研究所 | 一类炔基杂环类化合物及其应用 |
| EP3008051A4 (en) | 2013-06-12 | 2017-03-01 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| HK1223364A1 (zh) | 2013-06-28 | 2017-07-28 | Abbvie Inc. | 布罗莫结构域抑制剂 |
| US9399640B2 (en) * | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| US20150148372A1 (en) | 2013-11-26 | 2015-05-28 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015081280A1 (en) | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution |
| RU2692485C2 (ru) * | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| SMT202000133T1 (it) * | 2014-04-23 | 2020-05-08 | Incyte Corp | 1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet |
| JP6639497B2 (ja) * | 2014-11-10 | 2020-02-05 | ジェネンテック， インコーポレイテッド | ブロモドメインインヒビターおよびその使用 |
| MA40940A (fr) * | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| EP3632915A1 (en) | 2014-11-27 | 2020-04-08 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| AU2016209046A1 (en) * | 2015-01-23 | 2017-07-20 | Aclaris Therapeutics, Inc. | Heterocyclic ITK inhibitors for treating inflammation and cancer |
| WO2016123391A1 (en) | 2015-01-29 | 2016-08-04 | Genentech, Inc. | Therapeutic compounds and uses thereof |
| JP6512051B2 (ja) * | 2015-09-28 | 2019-05-15 | 株式会社Ｊｖｃケンウッド | 端末装置、通信システム、通信方法、プログラム |
-
2015
- 2015-11-09 MA MA040943A patent/MA40943A/fr unknown
- 2015-11-10 JP JP2017525075A patent/JP6669744B2/ja not_active Expired - Fee Related
- 2015-11-10 CN CN201580072359.2A patent/CN107207493B/zh not_active Expired - Fee Related
- 2015-11-10 EP EP15797766.1A patent/EP3218375B1/en active Active
- 2015-11-10 CN CN202310032629.3A patent/CN116003409A/zh active Pending
- 2015-11-10 WO PCT/US2015/060003 patent/WO2016077378A1/en not_active Ceased
- 2015-11-10 CN CN202211065963.0A patent/CN115583947A/zh active Pending
-
2017
- 2017-05-10 US US15/592,013 patent/US10183009B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017533249A5 (enExample) | ||
| JP2017533250A5 (enExample) | ||
| JP2017530176A5 (enExample) | ||
| Blake et al. | Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1 H-pyrazol-5-yl) amino) pyrimidin-4-yl) pyridin-2 (1 H)-one (GDC-0994), an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor in early clinical development | |
| AU2008236562B2 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | |
| CN101039673B (zh) | 用于治疗涉及细胞增殖的疾病的组合 | |
| TWI699355B (zh) | 喹唑啉化合物 | |
| Tan et al. | Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies | |
| TWI556820B (zh) | Ｈｓｐ９０抑制劑之組合 | |
| JP6669745B2 (ja) | ブロモドメインのインヒビターとしての置換ピロロピリジン | |
| TWI324159B (en) | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | |
| JP2017537100A5 (enExample) | ||
| JP6669744B2 (ja) | ブロモドメインのインヒビターとしての置換ピロロピリジン | |
| JP2017526696A5 (enExample) | ||
| BRPI0813999A2 (pt) | ciclopentanos de pirimidil como inibidores de akt proteína cinase | |
| EP4225383A1 (en) | Modulators of cell proliferation and uses thereof | |
| JP2018501287A5 (enExample) | ||
| JP2019512535A5 (enExample) | ||
| JP2017525740A5 (enExample) | ||
| JP2012515737A (ja) | メトトレキサートおよびｄｈｏｄｈ阻害剤を含む組合せ剤 | |
| JP2017501983A5 (enExample) | ||
| JP2015514796A5 (enExample) | ||
| CN104470509A (zh) | 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途 | |
| WO2022138944A1 (ja) | Ｓｗｉ／ｓｎｆ複合体機能異常がんの合成致死性に基づく治療法 | |
| JP2026501324A (ja) | 選択的ｂｅｔ阻害剤及びその使用 |